公开(公告)号：US11690872B2

公开(公告)日：2023-07-04

申请号：US16200308

申请日：2018-11-26

Applicant: Immatics US, Inc.

Inventor： Monique Dao ,  Steffen Walter ,  Melinda Mata ,  Aleksandra Nowicka ,  Yannick Bulliard ,  Sarah Missell ,  Sabrina Kuttruff-Coqui ,  Norbert Hilf

IPC: A61K35/17 ,  C12N5/0783 ,  A61K31/663 ,  A61K31/675 ,  A61K38/20 ,  C07K14/54 ,  C07K14/55 ,  C12N5/00 ,  C12N15/62 ,  C12N15/85 ,  A61K35/12 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K31/663 ,  A61K31/675 ,  A61K38/2013 ,  C07K14/5443 ,  C07K14/55 ,  C12N5/0018 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/62 ,  C12N15/8509 ,  A61K2035/122 ,  A61K2035/124 ,  C07K16/2809 ,  C12N2501/155 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2501/515 ,  C12N2501/998 ,  C12N2740/10043

Abstract: The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of γδ T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of γδ T cells while depleting α- and/or β-TCR positive cells. T cell populations comprising expanded γδ T cell and depleted or reduced α- and/or β-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.

公开(公告)号：US20190175650A1

公开(公告)日：2019-06-13

申请号：US16200308

申请日：2018-11-26

Applicant: Immatics US, Inc.

Inventor： Monique Dao ,  Steffen Walter ,  Melinda Mata ,  Aleksandra Nowicka ,  Yannick Bulliard

IPC: A61K35/17 ,  C12N5/0783 ,  C12N5/00 ,  C12N15/62 ,  A61K31/675 ,  A61K38/20 ,  C07K14/55 ,  C07K14/54 ,  C07K16/28 ,  A61K31/663 ,  C12N15/85

Abstract: The present disclosure relates to expansion and activation of T cells. In an aspect, the present disclosure relates to expansion and activation of γδ T cells that may be used for transgene expression. In another aspect, the disclosure relates to expansion and activation of γδ T cells while depleting α- and/or β-TCR positive cells. T cell populations comprising expanded γδ T cell and depleted or reduced α- and/or β-TCR positive cells are also provided for by the instant disclosure. The disclosure further provides for methods of using the disclosed T cell populations.